Poh Chin L, Cordina Rachael L, Iyengar Ajay J, Zannino Diana, Grigg Leeanne E, Wheaton Gavin R, Bullock Andrew, Ayer Julian, Alphonso Nelson, Gentles Thomas L, Celermajer David S, d'Udekem Yves
Heart Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Victoria, Australia.
Int J Cardiol Heart Vasc. 2021 Jul 7;35:100825. doi: 10.1016/j.ijcha.2021.100825. eCollection 2021 Aug.
This review identifies the predictors of late mortality and heart transplantation that remain relevant in the contemporary population of patients with a Fontan circulation, focusing on the potential impact of post-Fontan morbidities on the late outlook of these patients.
A total of 1561 patients who had survived the Fontan operation in Australia or New Zealand from 1975 to 2018 were included in this review. Over a median duration of 11.4 years, there was a total of 117 deaths (7%) and 32 heart transplantations (2%). Freedom from death and heart transplantation at 10, 20 and 35 years post Fontan surgery were 94% (95% CI 93-95%), 87% (95 %CI 85-90%) and 66% (95 %CI 57-78%) respectively. Being male, having an atriopulmonary Fontan, pre-Fontan atrioventricular valve intervention, or prolonged pleural effusions post Fontan were predictive of late death or heart transplantation. However, time-dependent variables such as the development of atrial arrhythmia, protein/losing enteropathy or late ventricular dysfunction were stronger predictors of the same outcome. Patients who developed a time-dependent risk factor had a freedom from death and heart transplantation rate of 54% (95 %CI 43-66) at 15 years and 44% (95 %CI 33-57) at 25 years post Fontan. However, 95% (95 %CI 91-99) of patients without any of the identified risk factors were free from death or heart transplantation rate at 25 years post Fontan.
In conclusion, the occurrence of post-operative complications such as PLE, arrhythmia and ventricular dysfunction will likely precede the late demise of these patients.
本综述确定了在当代Fontan循环患者群体中仍与晚期死亡率和心脏移植相关的预测因素,重点关注Fontan术后并发症对这些患者晚期预后的潜在影响。
本综述纳入了1975年至2018年在澳大利亚或新西兰接受Fontan手术且存活的1561例患者。在中位随访时间11.4年期间,共有117例死亡(7%)和32例心脏移植(2%)。Fontan手术后10年、20年和35年无死亡和心脏移植的生存率分别为94%(95%CI 93 - 95%)、87%(95%CI 85 - 90%)和66%(95%CI 57 - 78%)。男性、采用心房肺Fontan术式、Fontan术前房室瓣干预或Fontan术后长期胸腔积液是晚期死亡或心脏移植的预测因素。然而,诸如房性心律失常、蛋白丢失性肠病或晚期心室功能障碍等随时间变化的变量是同一结局更强的预测因素。出现随时间变化的危险因素的患者在Fontan术后15年无死亡和心脏移植的生存率为54%(95%CI 43 - 66),在25年时为44%(95%CI 33 - 57)。然而,95%(95%CI 91 - 99)没有任何已确定危险因素的患者在Fontan术后25年无死亡或心脏移植。
总之,诸如胸腔积液、心律失常和心室功能障碍等术后并发症的发生可能先于这些患者的晚期死亡。